A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports. Olaparib, a pill lacking the side effects of chemotherapy, can target an Achilles heel in prostate cancers with a weakness in their ability to repair damaged DNA.
from Top Health News -- ScienceDaily https://ift.tt/2YkR1PI
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
While sales to original equipment manufacturers declined 16.3% year on year in FY20, the replacement market sales declined by a modest 2.6% ...
-
India's passenger vehicle sales are expected to grow between 3-5 percent in the current fiscal year, after expanding at the slowest pace...
-
The earnings momentum has been quite resilient and the policy momentum quite focused towards improving the infrastructure and attractiveness...
No comments:
Post a Comment